- Previous Close
4.0000 - Open
3.7200 - Bid 3.8400 x --
- Ask 4.0800 x --
- Day's Range
3.7200 - 3.8200 - 52 Week Range
1.8700 - 4.9200 - Volume
3 - Avg. Volume
348 - Market Cap (intraday)
1.34B - Beta (5Y Monthly) 1.35
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1900 - Earnings Date Mar 28, 2025 - Mar 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jul 13, 2022
- 1y Target Est
--
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
www.cansinotech.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: CJH.F
View MorePerformance Overview: CJH.F
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CJH.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CJH.F
View MoreValuation Measures
Market Cap
1.40B
Enterprise Value
1.25B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.49
Price/Book (mrq)
1.60
Enterprise Value/Revenue
12.05
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-44.77%
Return on Assets (ttm)
--
Return on Equity (ttm)
-7.32%
Revenue (ttm)
846.34M
Net Income Avi to Common (ttm)
-378.88M
Diluted EPS (ttm)
-0.1900
Balance Sheet and Cash Flow
Total Cash (mrq)
3.28B
Total Debt/Equity (mrq)
41.52%
Levered Free Cash Flow (ttm)
--